Ginseng compounds: an update on their molecular mechanisms and medical applications - PubMed (original) (raw)
Review
Ginseng compounds: an update on their molecular mechanisms and medical applications
Jian-Ming Lü et al. Curr Vasc Pharmacol. 2009 Jul.
Abstract
Ginseng is one of the most widely used herbal medicines and is reported to have a wide range of therapeutic and pharmacological applications. Ginsenosides, the major pharmacologically active ingredients of ginseng, appear to be responsible for most of the activities of ginseng including vasorelaxation, antioxidation, anti-inflammation and anti-cancer. Approximately 40 ginsenoside compounds have been identified. Researchers now focus on using purified individual ginsenoside to reveal the specific mechanism of functions of ginseng instead of using whole ginseng root extracts. Individual ginsenosides may have different effects in pharmacology and mechanisms due to their different chemical structures. Among them the most commonly studied ginsenosides are Rb1, Rg1, Rg3, Re, Rd and Rh1. The molecular mechanisms and medical applications of ginsenosides have attracted much attention and hundreds of papers have been published in the last few years. The general purpose of this update is to provide information of recently described effects of ginsenosides on antioxidation, vascular system, signal transduction pathways and interaction with receptors. Their therapeutic applications in animal models and humans as well as the pharmacokinetics and toxicity of ginsenosides are also discussed in this review. This review concludes with some thoughts for future directions in the further development of ginseng compounds as effective therapeutic agents.
Figures
Fig. 1
Structure of selected ginsenosides. A. protopanaxadiols (PD). B. protopanaxatriols (PT). C. derivatives of PD and PT. D. new ginsenosides. Glc, β-D-glucose; Rha, α-L-rhamnose; Ara(p), αL-arabinose(pyranose); Ara(f), α-L-arabinose(furanose); Xyl, β-D-xylose; GlcUA, β-D-glucuronic acid; mal, malonyl; Ac, acetyl.
Similar articles
- Cardiovascular Diseases and Panax ginseng: A Review on Molecular Mechanisms and Medical Applications.
Kim JH. Kim JH. J Ginseng Res. 2012 Jan;36(1):16-26. doi: 10.5142/jgr.2012.36.1.16. J Ginseng Res. 2012. PMID: 23717100 Free PMC article. - Ginsenosides in vascular remodeling: Cellular and molecular mechanisms of their therapeutic action.
Zhu GX, Zuo JL, Xu L, Li SQ. Zhu GX, et al. Pharmacol Res. 2021 Jul;169:105647. doi: 10.1016/j.phrs.2021.105647. Epub 2021 May 6. Pharmacol Res. 2021. PMID: 33964471 Review. - A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases.
Lee CH, Kim JH. Lee CH, et al. J Ginseng Res. 2014 Jul;38(3):161-6. doi: 10.1016/j.jgr.2014.03.001. Epub 2014 Apr 3. J Ginseng Res. 2014. PMID: 25378989 Free PMC article. Review. - Neuroprotective Effects of Ginsenosides against Cerebral Ischemia.
Cheng Z, Zhang M, Ling C, Zhu Y, Ren H, Hong C, Qin J, Liu T, Wang J. Cheng Z, et al. Molecules. 2019 Mar 20;24(6):1102. doi: 10.3390/molecules24061102. Molecules. 2019. PMID: 30897756 Free PMC article. - Neuroprotection and mechanisms of ginsenosides in nervous system diseases: Progress and perspectives.
Zhou L, Tan F, Zhang X, Li Y, Yin W. Zhou L, et al. IUBMB Life. 2024 Nov;76(11):862-882. doi: 10.1002/iub.2862. Epub 2024 Jun 1. IUBMB Life. 2024. PMID: 38822647 Review.
Cited by
- Monoclonal antibody-based enzyme-linked immunosorbent assay for quantification of majonoside R2 as an authentication marker for Nngoc Linh and Lai Chau ginsengs.
Chaingam J, Van Huy L, Noguchi K, Nuntawong P, Vimolmangkang S, Yodsurang V, Yusakul G, Morimoto S, Sakamoto S. Chaingam J, et al. J Ginseng Res. 2024 Sep;48(5):474-480. doi: 10.1016/j.jgr.2024.05.004. Epub 2024 May 23. J Ginseng Res. 2024. PMID: 39263304 Free PMC article. - Therapeutic potential of ginsenoside Rg3 and Rf for Huntington's disease.
Lee M, Ban JJ, Won BH, Im W, Kim M. Lee M, et al. In Vitro Cell Dev Biol Anim. 2021 Jun;57(6):641-648. doi: 10.1007/s11626-021-00595-1. Epub 2021 Jun 14. In Vitro Cell Dev Biol Anim. 2021. PMID: 34128157 - Effect of Korean Red Ginseng on metabolic syndrome.
Yoon SJ, Kim SK, Lee NY, Choi YR, Kim HS, Gupta H, Youn GS, Sung H, Shin MJ, Suk KT. Yoon SJ, et al. J Ginseng Res. 2021 May;45(3):380-389. doi: 10.1016/j.jgr.2020.11.002. Epub 2020 Nov 12. J Ginseng Res. 2021. PMID: 34025131 Free PMC article. Review. - The Effectiveness of Traditional Chinese Medicine Combined With Surgery to Treat Granulomatous Mastitis: A Propensity-Matched Analysis.
Sawuer R, Wu C, Sun Z, Liu S. Sawuer R, et al. Front Oncol. 2022 Feb 10;12:833742. doi: 10.3389/fonc.2022.833742. eCollection 2022. Front Oncol. 2022. PMID: 35223513 Free PMC article. - Neuroprotective Effect of Several Phytochemicals and Its Potential Application in the Prevention of Neurodegenerative Diseases.
Wang J, Song Y, Gao M, Bai X, Chen Z. Wang J, et al. Geriatrics (Basel). 2016 Nov 12;1(4):29. doi: 10.3390/geriatrics1040029. Geriatrics (Basel). 2016. PMID: 31022822 Free PMC article. Review.
References
- Helms S. Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev. 2004;9:259–74. - PubMed
- Bames AS, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults. Adv Data. 2004;343:1–19. - PubMed
- Borchers AT, Keen CL, Stern JS, Gershwin ME. Inflammation and Native American medicine: the role of botanicals. Am J Clin Nutr. 2000;72:339–47. - PubMed
- Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr. 2001;73:1101–6. - PubMed
- Blumenthal M. Herb sales down in mainstream market, up in natural food stores. Herbalgram. 2002 summer;55:60.
Publication types
MeSH terms
Substances
Grants and funding
- R01 HL083471/HL/NHLBI NIH HHS/United States
- R21 AT003094-02/AT/NCCIH NIH HHS/United States
- R01 EB002436/EB/NIBIB NIH HHS/United States
- HL083471/HL/NHLBI NIH HHS/United States
- R01 HL083471-04W1/HL/NHLBI NIH HHS/United States
- R21 AT003094/AT/NCCIH NIH HHS/United States
- HL72716/HL/NHLBI NIH HHS/United States
- R01 HL072716/HL/NHLBI NIH HHS/United States
- R01 HL072716-04/HL/NHLBI NIH HHS/United States
- R01 DE015543-04/DE/NIDCR NIH HHS/United States
- R01 HL083471-04/HL/NHLBI NIH HHS/United States
- R01 DE015543/DE/NIDCR NIH HHS/United States
- R01 EB002436-04/EB/NIBIB NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous